Quite recently we found that prostaglandin I1 (PGI2) low affinity binding sites observed in normal thyroids and in benign thyroid adenomas were not demonstrable in thyroid cancers. Furthermore, PGI2 high affinity binding sites were significantly decreased in relation to the degree of differentiation of the cancer (Virgolini et al., 1988a) . Since various other groups (Garrity et al., 1983; Nassar et al., 1985; Okumura et al., 1985) investigated the properties of prostaglandin-binding sites in rat hepatic tissue showing important effects of prostaglandins via the mediation of cAMP (Brass & Garrity, 1985; Sweat et al., 1983) , and also regulatory mechanisms at the receptor level (Garrity et al., 1987) , we investigated prostaglandin E1 (PGE,)-binding sites in normal human hepatic tissue (Virgolini et al., 1988b) . Surprisingly we found an interspecies difference concerning the number of binding sites between rat and human liver. Since rat hepatomas have an increased PGE1-sensitive adenylate cyclase activity and produce increased amounts of cAMP (Allen et al., 1971; Bronstad et al., 1978 , Bronstad & Christofferson, 1981 , Chayoth et al., 1973 we addressed the question of whether the binding capacity for PGE1 would be affected in human hepatocellular cancers.
Materials and methods

Materials
Normal human hepatic tissue samples were obtained from six patients (4 female, 2 male, 37-67 years) undergoing surgery for various cancers of the abdominal tract. Tissue samples of hepatocellular cancers were obtained from six other patients (4 female, 2 male, 43-61 years) undergoing lobectomy. All the patients were without liver metastasis. The tissue samples derived were immediately placed in 1 mM NaHCO3-buffer (pH 7.5, 4°C) and controlled by routine histology (Haematoxylin and Eosin stain Neville (1968) as modified by Clarke et al. (1975) . The membranes floating on the top of the 42.4% sucrose were removed with a wooden spatula and taken up in buffer containing 50mM Tris-HCl (pH 7.8) and 5mM MgCl2, and washed three times. Thereafter, the pellet was resuspended in buffer at a protein concentration of about 100,ug 100p1-1 plasma membrane protein using the assay kit provided by Bio-Rad (Commassic Brilliant Blue G-250, Richmond, CA, USA). This membrane suspension was used within 30min for the receptor-study.
Filtration assay of 3H-PGE1-binding experiments
Finally in the tubes a total assay volume of 200,ul was incubated with the plasma membranes in a concentration of about 100Mg 100g1-1 protein for 30min at 4°C. Standardised assay conditions were obtained from studies on time and temperature dependency (Virgolini et al., 1988b Displacement of 3H-PGEl-binding to plasma membranes prepared from human hepatocellular cancers PGE1, PGE2, iloprost, PGF20 and PGD2 caused a dosedependent inhibition of 3H-PGE1-binding to plasma membranes of hepatocellular hepatoma (Figure 3) . The rankorder of potency was indicated by PGE1IPGE 2> PGI2 >PGD 2>PGF2V. There was no significant difference between normal hepatic tissue and hepatocellular cancer tissue.
Discussion
The major objective of the present study has been the evaluation of the in vitro binding of 3H-PGE1 to hepatocellular cancer tissue compared to normal hepatic tissue. Whereas the specific binding of 3H-PGE1 to normal hepatic plasma membranes could be subdivided in high affinity binding sites (Kd=3.8+1.9nM) with a low capacity and in low affinity binding sites (Kd=13.9+2.9nM), presenting the majority of the receptor population with a higher capacity, the specific binding of 3H-PGE1 to plasma membranes prepared from hepatocellular cancer tissue indicated a single HEPATOCELLULAR CANCER AND PGE1 409 class of lower affinity binding sites (Kd = 12.1 + 2.8 nM) exhibiting a significantly lower capacity than at normal hepatic plasma membranes (P <0.005).
Although we could only study six hepatocellular cancers, the loss of the higher affinity 3H-PGE1-binding sites seems to reflect a common event for the malignant hepatoma. A similar alteration of the binding capacity was recently obtained for thyroid cancers with respect to the 3H-PGE1-binding sites (Virgolini et al., 1988a) . It is of interest that some authors reported on a more increased PGE1-sensitive adenylate cyclase activity in rat hepatomas (Allen et al., 1971; Bronstad & Christofferson, 1981; Chayoth et al., 1973) . Apart from an interspecies difference in the binding capacities of rat and human hepatic plasma membranes (Virgolini et al., 1988b) this demonstration might also implicate a down-regulation mechanism at the prostaglandin receptor level. However, the role of prostaglandins in cancer is not clear at all. The role of the arachidonic acid metabolites in physiological and pathophysiological states is currently under intensive investigation and the biological action of these compounds has been implicated in many key regulatory processes. Therefore, it is not unreasonable to predict that these compounds may have a central role in the initiation and regulation of the spectrum of diseases which we functionally call cancer.
